Time-to-event analyses according to duration of bortezomib therapy in patients achieving CR. Kaplan-Meier analyses of CR duration (time from CR to subsequent therapy) in (A) all patients achieving CR and (B) patients achieving early CR who received < 9 versus 9 cycles of bortezomib, excluding those who discontinued early because of PD, plus analyses of CR duration (C) and TNT (D) in patients achieving early versus late CR who completed all 9 cycles of bortezomib.